- Home
- SFL vs ELVN Comparison
SFL vs ELVN Comparison
Compare SFL & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SFL
- ELVN
- Stock Information
- Founded
- SFL 2003
- ELVN 2016
- Country
- SFL Bermuda
- ELVN United States
- Employees
- SFL N/A
- ELVN N/A
- Industry
- SFL Marine Transportation
- ELVN Biotechnology: Pharmaceutical Preparations
- Sector
- SFL Consumer Discretionary
- ELVN Health Care
- Exchange
- SFL Nasdaq
- ELVN Nasdaq
- Market Cap
- SFL 1.1B
- ELVN 927.8M
- IPO Year
- SFL N/A
- ELVN 2020
- Fundamental
- Price
- SFL $8.71
- ELVN $21.60
- Analyst Decision
- SFL Strong Buy
- ELVN Strong Buy
- Analyst Count
- SFL 1
- ELVN 5
- Target Price
- SFL $13.00
- ELVN $39.60
- AVG Volume (30 Days)
- SFL 1.1M
- ELVN 593.2K
- Earning Date
- SFL 08-13-2025
- ELVN 08-12-2025
- Dividend Yield
- SFL 12.15%
- ELVN N/A
- EPS Growth
- SFL N/A
- ELVN N/A
- EPS
- SFL 0.41
- ELVN N/A
- Revenue
- SFL $852,590,000.00
- ELVN N/A
- Revenue This Year
- SFL N/A
- ELVN N/A
- Revenue Next Year
- SFL $3.20
- ELVN N/A
- P/E Ratio
- SFL $21.91
- ELVN N/A
- Revenue Growth
- SFL 6.58
- ELVN N/A
- 52 Week Low
- SFL $6.78
- ELVN $13.30
- 52 Week High
- SFL $14.14
- ELVN $30.03
- Technical
- Relative Strength Index (RSI)
- SFL 58.71
- ELVN 56.18
- Support Level
- SFL $8.66
- ELVN $18.53
- Resistance Level
- SFL $8.98
- ELVN $24.11
- Average True Range (ATR)
- SFL 0.21
- ELVN 1.96
- MACD
- SFL 0.00
- ELVN 0.16
- Stochastic Oscillator
- SFL 58.00
- ELVN 57.89
About SFL SFL Corporation Ltd
SFL Corp Ltd is an international ship-owning and chartering company. The company is engaged in transporting crude oil and oil products, dry bulk and containerized cargoes, freight of rolling cargo, and offshore drilling and related activities.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.